Protalix BioTherapeutics awarded executive Naos Yaron 168,000 derivative securities across two transactions on 2026-09-03 at $0 per share. Yaron owned 56,000 derivative securities after the transactions, giving investors a specific view of the executive’s reported derivative-security position and the award’s recorded transaction terms.
Key Highlights
- Naos Yaron owned 56,000 derivative securities after the transactions.
- The transactions were recorded at $0 per share.
- Yaron serves as Protalix BioTherapeutics’ Sr. VP and COO.
Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded Naos Yaron 168,000 derivative securities across two transactions. The transactions took place on 3 September 2026 at $0 per share.
168,000 Derivative Securities Awarded
Naos Yaron, the company’s Sr. VP and COO, received the derivative securities through two separate transactions. Both transactions carried transaction code A. The recorded price was $0 per share. Yaron owned 56,000 derivative securities following the transactions.
FAQs
Q: How many derivative securities did Naos Yaron receive from Protalix BioTherapeutics?
A: Naos Yaron received 168,000 derivative securities from Protalix BioTherapeutics across two separate transactions. The Form 4 filing identifies both transactions as occurring on 3 September 2026.
Q: What was the price per share for Naos Yaron’s transactions?
A: The transactions involving Naos Yaron’s derivative securities were recorded at $0 per share. Following those transactions, he owned 56,000 derivative securities of Protalix BioTherapeutics.
Q: What is Naos Yaron’s role at Protalix BioTherapeutics?
A: Naos Yaron is Protalix BioTherapeutics’ Sr. VP and COO. The filing states that he was awarded derivative securities in two transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.